Brief: Reneo Pharmaceuticals Announces Results From Pivotal Stride Study Of Mavodelpar In Primary Mitochondrial Myopathies

Onkure Therapeutics

14/12/2023 14:18

Dec 14 (Reuters) - Reneo Pharmaceuticals Inc  RPHM.O :
    * RENEO PHARMACEUTICALS ANNOUNCES RESULTS FROM PIVOTAL
STRIDE
STUDY OF MAVODELPAR IN PRIMARY MITOCHONDRIAL MYOPATHIES (PMM)
    * RENEO PHARMACEUTICALS INC -
    * RENEO PHARMACEUTICALS INC - THE STRIDE STUDY DID NOT MEET
ITS
PRIMARY OR SECONDARY EFFICACY ENDPOINT
    * RENEO PHARMACEUTICALS INC - COMPANY TO SUSPEND MAVODELPAR
DEVELOPMENT AND IMPLEMENT A WORKFORCE REDUCTION
    * RENEO PHARMACEUTICALS INC - WORKFORCE REDUCTION OF
APPROXIMATELY
70%
    * RENEO PHARMACEUTICALS INC - SUSPENSION OF ONGOING STRIDE
AHEAD
STUDY AND ALL OTHER MAVODELPAR DEVELOPMENT ACTIVITIES
    * RENEO PHARMACEUTICALS INC - INTENDS TO IMPLEMENT IMMEDIATE
COST
SAVINGS INITIATIVES

Source text for Eikon:  ID:nGNXzC8qJ 
Further company coverage:  RPHM.O 

 ((Reuters.Briefs@thomsonreuters.com;))